Aeterna Zentaris receives complete response letter
November 06, 2014 at 12:15 PM EST
The
Food and Drug Administration issued Aeterna Zentaris Inc. (Nasdaq: AEZS) a
complete response letter denying approval of the New Drug Application
for Macrilen to treat adult growth hormone deficiency sending shares of the biopharmaceutical plunging 62 cents to $0.67.
